Strides Pharma Science Limited (STAR.BO)
INR 593.95
(2.87%)
INR 593.95
(2.87%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 5.22 Billion INR | 322.78% |
| 2022 | 1.23 Billion INR | 149.06% |
| 2021 | -2.51 Billion INR | -180.0% |
| 2020 | 3.14 Billion INR | 66.95% |
| 2019 | 1.88 Billion INR | 120.61% |
| 2018 | 855.14 Million INR | -66.62% |
| 2017 | 2.56 Billion INR | -36.5% |
| 2016 | 4.03 Billion INR | 40.29% |
| 2015 | 2.87 Billion INR | 64.4% |
| 2014 | 1.74 Billion INR | 9.44% |
| 2013 | 1.59 Billion INR | 87.36% |
| 2012 | 853.14 Million INR | -80.38% |
| 2011 | 4.34 Billion INR | 34.88% |
| 2010 | 3.22 Billion INR | 210.63% |
| 2009 | 1.03 Billion INR | -78.57% |
| 2008 | 4.84 Billion INR | 389.78% |
| 2007 | 988.67 Million INR | -8.85% |
| 2006 | 1.08 Billion INR | 14.89% |
| 2005 | 944.06 Million INR | 11.43% |
| 2004 | 847.2 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 1.85 Billion INR | 10.03% |
| 2024 Q1 | 1.68 Billion INR | -6.44% |
| 2023 FY | 5.22 Billion INR | 322.78% |
| 2023 Q3 | 1.42 Billion INR | 53.28% |
| 2023 Q2 | 930.22 Million INR | -13.07% |
| 2023 Q4 | 1.79 Billion INR | 26.22% |
| 2023 Q1 | 1.07 Billion INR | 13.08% |
| 2022 Q3 | 561.21 Million INR | 149.83% |
| 2022 Q4 | 946.28 Million INR | 68.61% |
| 2022 Q1 | -92.1 Million INR | 51.97% |
| 2022 FY | 1.23 Billion INR | 149.06% |
| 2022 Q2 | 224.64 Million INR | 343.91% |
| 2021 Q3 | -562.91 Million INR | 2.34% |
| 2021 Q1 | -1.1 Billion INR | -202.7% |
| 2021 Q2 | -576.37 Million INR | 47.71% |
| 2021 Q4 | -191.74 Million INR | 65.94% |
| 2021 FY | -2.51 Billion INR | -180.0% |
| 2020 Q3 | 1.3 Billion INR | 19.18% |
| 2020 FY | 3.14 Billion INR | 66.95% |
| 2020 Q2 | 1.09 Billion INR | -27.02% |
| 2020 Q4 | 1.07 Billion INR | -17.73% |
| 2020 Q1 | 1.49 Billion INR | 281.87% |
| 2019 Q2 | 760.9 Million INR | 11.52% |
| 2019 Q4 | -824.7 Million INR | -156.36% |
| 2019 Q1 | 682.32 Million INR | 363.78% |
| 2019 FY | 1.88 Billion INR | 120.61% |
| 2019 Q3 | 1.46 Billion INR | 92.3% |
| 2018 Q3 | -58.3 Million INR | -161.5% |
| 2018 FY | 855.14 Million INR | -66.62% |
| 2018 Q4 | 147.12 Million INR | 352.35% |
| 2018 Q2 | 94.8 Million INR | -15.05% |
| 2018 Q1 | 111.6 Million INR | -81.01% |
| 2017 Q2 | 840.2 Million INR | 24.44% |
| 2017 Q3 | 1.05 Billion INR | 25.49% |
| 2017 Q4 | 587.7 Million INR | -44.26% |
| 2017 Q1 | 675.2 Million INR | -56.44% |
| 2017 FY | 2.56 Billion INR | -36.5% |
| 2016 Q2 | 1.62 Billion INR | 53.95% |
| 2016 FY | 4.03 Billion INR | 40.29% |
| 2016 Q3 | 1.28 Billion INR | -21.27% |
| 2016 Q4 | 1.55 Billion INR | 20.81% |
| 2016 Q1 | 1.05 Billion INR | -12.6% |
| 2015 FY | 2.87 Billion INR | 64.4% |
| 2015 Q2 | 1.06 Billion INR | 59.35% |
| 2015 Q4 | 1.21 Billion INR | 4.63% |
| 2015 Q3 | 1.15 Billion INR | 8.82% |
| 2015 Q1 | 667.6 Million INR | 67.35% |
| 2014 Q3 | 508.21 Million INR | 8.98% |
| 2014 FY | 1.74 Billion INR | 9.44% |
| 2014 Q2 | 466.35 Million INR | 60.12% |
| 2014 Q1 | 291.24 Million INR | 0.0% |
| 2014 Q4 | 398.92 Million INR | -21.51% |
| 2013 FY | 1.59 Billion INR | 87.36% |
| 2012 FY | 853.14 Million INR | -80.38% |
| 2011 FY | 4.34 Billion INR | 34.88% |
| 2010 FY | 3.22 Billion INR | 210.63% |
| 2009 FY | 1.03 Billion INR | -78.57% |
| 2008 FY | 4.84 Billion INR | 389.78% |
| 2007 FY | 988.67 Million INR | -8.85% |
| 2006 FY | 1.08 Billion INR | 14.89% |
| 2005 FY | 944.06 Million INR | 11.43% |
| 2004 FY | 847.2 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 9.244% |
| Aurobindo Pharma Limited | 42.2 Billion INR | 87.617% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 41.801% |
| Granules India Limited | 6.81 Billion INR | 23.338% |
| Indoco Remedies Limited | 1.29 Billion INR | -304.303% |
| Achyut Healthcare Limited | 4.43 Million INR | -117651.465% |
| Ajanta Pharma Limited | 19.67 Billion INR | 73.442% |
| Alkem Laboratories Limited | 19.46 Billion INR | 73.149% |
| Alpa Laboratories Limited | 184.49 Million INR | -2732.463% |
| Brooks Laboratories Limited | 14.44 Million INR | -36089.82% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | -204.268% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | -324.517% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 92.284% |
| Eris Lifesciences Limited | 5.18 Billion INR | -0.851% |
| FDC Limited | 2.98 Billion INR | -74.998% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 19.632% |
| Gufic Biosciences Limited | 1.32 Billion INR | -292.945% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | -18.216% |
| Ipca Laboratories Limited | 7.98 Billion INR | 34.519% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | -928.44% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | 3539.006% |
| Lasa Supergenerics Limited | -458 Million INR | 1240.994% |
| Laurus Labs Limited | 3.94 Billion INR | -32.346% |
| Lupin Limited | 28.04 Billion INR | 81.366% |
| Mankind Pharma Limited | 21.51 Billion INR | 75.714% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Medico Remedies Limited | 100.3 Million INR | -5110.179% |
| Megasoft Limited | -121.1 Million INR | 4415.142% |
| NATCO Pharma Limited | 25.96 Billion INR | 79.871% |
| Piramal Pharma Limited | 4.55 Billion INR | -14.679% |
| RPG Life Sciences Limited | 2.29 Billion INR | -127.972% |
| Sigachi Industries Limited | 1.47 Billion INR | -254.558% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 94.99% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | -13.416% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -1996.605% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Wanbury Limited | 569.71 Million INR | -817.266% |
| Windlas Biotech Limited | 1.29 Billion INR | -302.329% |
| ZIM Laboratories Limited | 253.82 Million INR | -1958.792% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 87.877% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 226.993% |
| Divi's Laboratories Limited | 33.08 Billion INR | 84.203% |
| Hester Biosciences Limited | 364.81 Million INR | -1332.474% |
| Procter & Gamble Health Limited | 2.78 Billion INR | -87.574% |
| Amrutanjan Health Care Limited | 457.54 Million INR | -1042.144% |
| Bal Pharma Limited | 233.9 Million INR | -2134.121% |
| Venus Remedies Limited | 534.65 Million INR | -877.425% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | -67.059% |
| Nectar Lifesciences Limited | 923.8 Million INR | -465.683% |
| Shilpa Medicare Limited | 1.36 Billion INR | -282.487% |
| Aarti Drugs Limited | 7.14 Billion INR | 26.899% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | -227.268% |
| Suven Life Sciences Limited | -1.22 Billion INR | 526.311% |
| Ind-Swift Limited | 1.22 Billion INR | -326.261% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | 63.412% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 235.633% |
| Themis Medicare Limited | 392.58 Million INR | -1231.115% |
| Hikal Limited | 32.11 Million INR | -16174.712% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 79.373% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Novartis India Limited | 626.5 Million INR | -734.128% |
| Wockhardt Limited | -670 Million INR | 879.972% |
| Jubilant Pharmova Limited | 5.18 Billion INR | -0.709% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | -57524.687% |
| Neuland Laboratories Limited | 5.31 Billion INR | 1.735% |
| Morepen Laboratories Limited | 4.17 Billion INR | -25.204% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -2411.805% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -18932.013% |